Sarepta Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 73 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 22.42.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Media Coverage
The current financial score of Sarepta Therapeutics Inc is 6.96, ranking 127 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 730.80M, representing a year-over-year decrease of 1.89%, while its net profit experienced a year-over-year decrease of 173.96%.
Key Metrics
The current valuation score of Sarepta Therapeutics Inc is 7.20, ranking 88 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 28.16, which is 1212.14% below the recent high of 369.56 and 259.93% above the recent low of -45.04.
The current earnings forecast score of Sarepta Therapeutics Inc is 6.52, ranking 130 out of 155 in the Pharmaceuticals industry. The average price target is 17.50, with a high of 185.00 and a low of 5.00.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
The current price momentum score of Sarepta Therapeutics Inc is 6.13, ranking 129 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 21.52 and the support level at 15.55, making it suitable for range-bound swing trading.
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
The current institutional shareholding score of Sarepta Therapeutics Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 90.53%, representing a quarter-over-quarter increase of 4.25%. The largest institutional shareholder is James Simons, holding a total of 1.67M shares, representing 1.58% of shares outstanding, with 1.00% increase in holdings.
The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Sarepta Therapeutics Inc is 3.68, ranking 98 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.24. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
